Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes

In Vivo

Volumn 17, Issue 2, 2003, Pages 177-180

  Nakamura, Norio ^a   Yamazaki, Katsuya ^b   Satoh, Akira ^b   Urakaze, Masaharu ^b   Kobayashi, Masashi ^b   Yamabe, Hideaki ^a   Osawa, Hiroshi ^a   Shirato, Ken Ichi ^a   Sugawara, Toshiyuki ^a   Nakamura, Masayuki ^a   Tamura, Michiko ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Aldose reductase inhibitors; Carboxymethyl lysine (CML); Eparlestat; Glycation end products (AGE); Type 2 DM

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; CARBOXYMETHYLLYSINE; EPALRESTAT; GLUCOSE; HEMOGLOBIN A1C; PROTEIN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; ENZYME MECHANISM; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PROTEIN BLOOD LEVEL; SERUM; SIDE EFFECT;

EID: 0037532456     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brownlee M, Cerami A and Vlassara H: Advanced glycosylation end products in tissue and the biomedical basis of diabetic complication. N Engl J Med 318: 1315-1321, 1988.
2. Monnier VM: Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 451: 13105-13111, 1990.
3. Miyata S and Monnier VM: Immunohistochemical detection of advanced glycosylation end products in diabetic tissue using monoclonal antibody to pyrraline. J Clin Invest 89: 1102-1112, 1992.
4. Konishi Y, Hayase F and Kato H: Novel imidazolones compound formed by the advanced Maillard reaction of 3-deoxyglucosone and arginine residues in proteins. Biosci Biotech Biochem 58; 1953-1955, 1994.
5. Hayase F, Konishi Y and Kato H: Identification of the modified structure of arginine residues in proteins with 3-deoxyglucosone, a Maillard reaction intermediate. Biosci Biotech Biochem 59: 1407-1411, 1995.
6. ε(carboxymethyl) lysine in dialysis-related amyloidosis. Kidney Int 50: 1303-13091, 1996.
7. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Miyazaki S, Tatemichi N and Takei Y: Modification of β2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49: 861-867, 1996.
8. Hayase F, Nagaraj RH, Miyata S, Njoroge FG and Monnier VM: Aging of proteins: Immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 264: 3758-37647 1989.
9. Dyer DG, Blackledge JA, Thorpe SR and Baynes JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose. J Biol Chem 266L: 11654-11660, 1991.
10. ε-carboxymethyllysine as a degeneration product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894, 1986.
11. ε-(carboxymethyl) hydroxylysine in human skin collagen. Biochemistry 30: 1205-12107, 1991.
12. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR and Baynes JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993.
13. ε-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468, 1997.
14. Kilhovd BK, Thorsby P, Berg TJ, Hanssen KF and Birkeland KI: Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22: 1543-15481, 1999.
15. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K and Tsukada Y: Increased serum levels of advanced glycation end-products and diabetic complications. Diab Res Clin Pract 41: 131-137, 1998.
16. Kato H, Yamamoto M and Fujimaki M: Mechanismus of browning degradation of D-fructose in special comparison with D-glucose-glycine reaction. Agric Biol Chem 33: 939-948, 1969.
17. Takano S, Kimura S, Ohdama S and Aoki N: Plasma thrombomodulin in health and diseases. Blood 76:2024-20291, 1990.
18. Blann AD and Taberner DA: Annotation: A reliable marker of endothelial cell dysfunction: Does it exist? Br J Haematol 90: 244-248, 1995.
19. Hamada Y, Araki N, Horiuchi S and Hotta N: Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant 11 (Suppl. 5): 95-98, 1996.
20. Iwashima Y, Sato T, Watanabe K, Oshima E, Hiraishi S, Ishii H, Kazama M and Makino I: Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 39: 983-988, 1990.
21. Ikeda T, Iwaki K and Tanaka Y: Long-term effect of eparlestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. Diab Res Clin Pract 43: 193-198, 1999.
22. Iso K, Tada H, Kuboki K and Inokuchi T: Long-term effect of eparlestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patients. J Diab Compl 15: 241-244, 2001.
23. Tsukushi S, Katsuzaki T, Aoyama I, Takayama F, Miyazaki T, Shimokawa K and Niwa T: Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway. Kidney Int 55: 1970-1976, 1999.